The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Non-small cell lung cancer (NSCLC) classification has evolved beyond histology to incorporate clinical and molecular data.
• Targeted therapies and immuno-oncology agents have improved outcomes for metastatic NSCLC.
• Recent advancements are beginning to impact the management of resectable NSCLC.

Purpose of the Study:

• To review the evolution of NSCLC understanding and its therapeutic implications.
• To highlight the integration of molecular biomarkers in NSCLC treatment.
• To discuss the application of targeted therapies and immuno-oncology in resectable NSCLC.

Main Methods:

• Literature review of NSCLC classification and treatment strategies.
• Analysis of FDA-approved targeted therapies for specific driver alterations.
• Synthesis of data on immuno-oncology agents and their impact on survival.

Main Results:

• NSCLC management now integrates histology, clinical data, and molecular profiling.
• Numerous targeted therapies are available for NSCLC patients with specific genetic alterations (e.g., EGFR, ALK, KRAS).
• Immuno-oncology has shown population-level survival benefits in NSCLC.

Conclusions:

• The nuanced understanding of NSCLC, driven by molecular insights, is increasingly applied to resectable disease.
• Biomarker-driven therapies represent a paradigm shift in NSCLC treatment.
• Further integration of molecular diagnostics is crucial for optimizing NSCLC patient care.